deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT03015740

Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer

Phase I/II Trial of MGCD516 Combined With Nivolumab in Patients With Advanced Clear Cell Renal Cell Cancer That Progressed on Prior VEGF-Targeted Therapy

Sponsor: M.D. Anderson Cancer Center

Conditions Clear Cell Renal Cell Carcinoma Metastatic Kidney Carcinoma Stage III Renal Cell Cancer AJCC v7 Stage IV Renal Cell Cancer AJCC v7
Interventions Laboratory Biomarker Analysis Nivolumab Quality-of-Life Assessment Questionnaire Administration Sitravatinib
Updated 20 times since 2017 Last updated: Oct 24, 2024 Started: Apr 23, 2017 Primary completion: Sep 6, 2022 Completion: Sep 6, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03015740, this PHASE1/PHASE2 trial focuses on Clear Cell Renal Cell Carcinoma and Metastatic Kidney Carcinoma and remains completed. Sponsored by M.D. Anderson Cancer Center, it has been updated 20 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Sep 2017 · 4 months · monthly snapshot~Sep 2017 – ~Jun 2018 · 9 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Jan 2019 · 5 months · monthly snapshot~Jan 2019 – ~May 2019 · 4 months · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~May 2020 · 8 months · monthly snapshot~May 2020 – ~Jul 2020 · 2 months · monthly snapshot~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshot~Jan 2021 – ~Mar 2022 · 14 months · monthly snapshot~Mar 2022 – ~Nov 2022 · 8 months · monthly snapshot~Nov 2022 – ~Jun 2023 · 7 months · monthly snapshot~Jun 2023 – ~Jul 2024 · 13 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – present · 19 months · monthly snapshot

Change History

20 versions recorded

  1. Dec 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Sep 2024 — Dec 2024 [monthly]

    Completed PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Jun 2023 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  5. Nov 2022 — Jun 2023 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 15 earlier versions

  1. Mar 2022 — Nov 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Jan 2021 — Mar 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Jul 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. May 2020 — Jul 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  5. Sep 2019 — May 2020 [monthly]

    Recruiting PHASE1_PHASE2

  6. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE1_PHASE2

  7. Jul 2019 — Aug 2019 [monthly]

    Recruiting PHASE1_PHASE2

  8. Jun 2019 — Jul 2019 [monthly]

    Recruiting PHASE1_PHASE2

  9. May 2019 — Jun 2019 [monthly]

    Recruiting PHASE1_PHASE2

  10. Jan 2019 — May 2019 [monthly]

    Recruiting PHASE1_PHASE2

  11. Aug 2018 — Jan 2019 [monthly]

    Recruiting PHASE1_PHASE2

  12. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE1_PHASE2

  13. Sep 2017 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  14. May 2017 — Sep 2017 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  15. Feb 2017 — May 2017 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • M.D. Anderson Cancer Center
  • National Cancer Institute (NCI)
Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations